Laurent Dercle1, Samy Ammari2, Romain-David Seban2, Lawrence H Schwartz3, Roch Houot4, Nizar Labaied5, Fatima-Zohra Mokrane6, Julien Lazarovici7, Alina Danu7, Aurélien Marabelle8, Vincent Ribrag7, Jean-Marie Michot7. 1. Gustave Roussy, Université Paris-Saclay, Inserm UMR1015, France; Gustave Roussy, Université Paris-Saclay, Département D'imagerie Médicale, Villejuif F-94805, France; Department of Radiology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA. Electronic address: laurent.dercle@gmail.com. 2. Gustave Roussy, Université Paris-Saclay, Département D'imagerie Médicale, Villejuif F-94805, France. 3. Department of Radiology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY, USA. 4. CHU Rennes, Service Hematologie Clinique, Rennes, France. 5. Department of Pathology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France. 6. Department of Radiology, Toulouse University, France. 7. Department of Medicine Oncology, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France; Gustave Roussy, Université Paris-Saclay, Département D'hématologie, Villejuif F-94805, France. 8. Gustave Roussy, Université Paris-Saclay, Inserm UMR1015, France; Drug Development Department, Gustave Roussy Comprehensive Cancer Center, F-94805 Villejuif, France.
Abstract
BACKGROUND: We aimed to define the depth and time of maximal anti-tumour response to programmed death-1 blockade antibodies (anti-PD1) in heavily pre-treated patients with classical Hodgkin lymphoma (HL). To this end, we evaluated the kinetics of response for up to two years. MATERIALS AND METHODS: The 18F-FDG positron-emission tomography (PET) and contrast-enhanced computerised tomography (CECT) data of all relapsed or refractory HL treated at Gustave Roussy, Villejuif, France, from 2013 to 2015 were retrospectively reviewed according to the International Harmonisation Project Cheson 2014 criteria and the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC). RESULTS: Sixteen patients were included. The median (range) treatment duration was 18.4 (2.8-23.7) months. Fifty-six percent of patients (9/16) achieved an objective response at 3 months, including 19% (3/16) of complete response. Seventeen percent (1/6) of partial responders at 3 months were converted in a complete response. 22% (2/9) of responders at 3 months relapsed before one year. The nadir was reached at 12.7 (3.0-23.0) months. The median (range) depth of response at nadir was -77% (-50% to 100%). CONCLUSION: We concluded that complete metabolic responses occurred within 6 months, a minority of partial responses were converted in complete response, and the median nadir was observed one year after treatment initiation. These data could help to better define the optimal treatment strategy by PET or CECT-directed approaches.
BACKGROUND: We aimed to define the depth and time of maximal anti-tumour response to programmed death-1 blockade antibodies (anti-PD1) in heavily pre-treated patients with classical Hodgkin lymphoma (HL). To this end, we evaluated the kinetics of response for up to two years. MATERIALS AND METHODS: The 18F-FDG positron-emission tomography (PET) and contrast-enhanced computerised tomography (CECT) data of all relapsed or refractory HL treated at Gustave Roussy, Villejuif, France, from 2013 to 2015 were retrospectively reviewed according to the International Harmonisation Project Cheson 2014 criteria and the LYmphoma Response to Immunomodulatory therapy Criteria (LYRIC). RESULTS: Sixteen patients were included. The median (range) treatment duration was 18.4 (2.8-23.7) months. Fifty-six percent of patients (9/16) achieved an objective response at 3 months, including 19% (3/16) of complete response. Seventeen percent (1/6) of partial responders at 3 months were converted in a complete response. 22% (2/9) of responders at 3 months relapsed before one year. The nadir was reached at 12.7 (3.0-23.0) months. The median (range) depth of response at nadir was -77% (-50% to 100%). CONCLUSION: We concluded that complete metabolic responses occurred within 6 months, a minority of partial responses were converted in complete response, and the median nadir was observed one year after treatment initiation. These data could help to better define the optimal treatment strategy by PET or CECT-directed approaches.
Authors: Randy Yeh; Megan H Trager; Emanuelle M Rizk; Grace G Finkel; Luke W Barker; Richard D Carvajal; Larisa J Geskin; Gary K Schwartz; Lawrence Schwartz; Laurent Dercle; Yvonne M Saenger Journal: Clin Nucl Med Date: 2020-04 Impact factor: 7.794
Authors: Reid W Merryman; Nicole A Carreau; Ranjana H Advani; Michael A Spinner; Alex F Herrera; Robert Chen; Sarah Tomassetti; Radhakrishnan Ramchandren; Muhammad Hamid; Sarit Assouline; Raoul Santiago; Nina Wagner-Johnston; Suman Paul; Jakub Svoboda; Steven M Bair; Stefan K Barta; Yang Liu; Sunita Nathan; Reem Karmali; Madelyn Burkart; Pallawi Torka; Kevin A David; Catherine Wei; Frederick Lansigan; Lukas Emery; Daniel Persky; Sonali M Smith; James Godfrey; Julio Chavez; Jonathan B Cohen; Andrea B Troxel; Catherine Diefenbach; Philippe Armand Journal: Oncologist Date: 2020-04-28
Authors: Romain-David Seban; John S Nemer; Aurélien Marabelle; Randy Yeh; Eric Deutsch; Samy Ammari; Antoine Moya-Plana; Fatima-Zohra Mokrane; Robyn D Gartrell; Grace Finkel; Luke Barker; Amélie E Bigorgne; Lawrence H Schwartz; Yvonne Saenger; Caroline Robert; Laurent Dercle Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-25 Impact factor: 9.236
Authors: Laetitia Vercellino; Dorine de Jong; Laurent Dercle; Benoit Hosten; Brian Braumuller; Jeeban Paul Das; Aileen Deng; Antoine Moya-Plana; Camry A'Keen; Randy Yeh; Pascal Merlet; Barouyr Baroudjian; Mary M Salvatore; Kathleen M Capaccione Journal: Diagnostics (Basel) Date: 2022-04-29
Authors: Marcus Unterrainer; Michael Ruzicka; Matthias P Fabritius; Lena M Mittlmeier; Michael Winkelmann; Johannes Rübenthaler; Matthias Brendel; Marion Subklewe; Michael von Bergwelt-Baildon; Jens Ricke; Wolfgang G Kunz; Clemens C Cyran Journal: Eur Radiol Exp Date: 2020-11-17
Authors: Ephraïm Partouche; Randy Yeh; Thomas Eche; Laura Rozenblum; Nicolas Carrere; Rosine Guimbaud; Lawrence O Dierickx; Hervé Rousseau; Laurent Dercle; Fatima-Zohra Mokrane Journal: Front Oncol Date: 2021-07-14 Impact factor: 6.244